Raleigh Capital Management »

Allogene Therapeutics shares owned by Raleigh Capital Management

Quarter-by-quarter ownership of Allogene Therapeutics (ALLO) shares owned by Raleigh Capital Management from 13F filings

Historical chart of Raleigh Capital Management investment in Allogene Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Allogene Therapeutics held by Raleigh Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Allogene Therapeutics by Raleigh Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $8.8k 2.8k 3.21

More positions owned by Raleigh Capital Management

Ishares Tr Core S&p500 Etf (IVV)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Ssga Active Tr Spdr Ssga Fxd (FISR)
Ssga Active Tr Spdr Ssga Us Sct (XLSR)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Philip Morris International (PM)
Verizon Communications (VZ)
Spdr Index Shs Fds Portfolio Emg Mk (SPEM)
Totalenergies Se Sponsored Ads (TTE)
Duke Energy Corp Com New (DUK)
Apple (AAPL)
Microsoft Corporation (MSFT)
Southern Company (SO)
Spdr Ser Tr Portfolio Agrgte (SPAB)
Abbvie (ABBV)

View all positions for Raleigh Capital Management

Top funds holding Allogene Therapeutics

Tpg Gp A
Vanguard Group
Jpmorgan Chase & Co
PRIMECAP Management Company
Citadel Advisors
Goldman Sachs Group
T. Rowe Price Associates
Two Sigma Investments
Millennium Management
Vida Ventures Advisors
Dimensional Fund Advisors
Two Sigma Advisers
Caxton Associates
Nordea Investment Management Ab
Charles Schwab Investment Management

View all funds holding Allogene Therapeutics